BS_VMEX27TN
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 25.952693823915897
- age_years
- 13.34
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.473
- G2M_CHECKPOINT+0.429
- DNA_REPAIR+0.340
- MYC_TARGETS_V1+0.315
- SPERMATOGENESIS+0.251
- MITOTIC_SPINDLE+0.205
- WNT_BETA_CATENIN_SIGNALING+0.036
- OXIDATIVE_PHOSPHORYLATION-0.031
- PANCREAS_BETA_CELLS-0.032
- PEROXISOME-0.079
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.608
- INFLAMMATORY_RESPONSE-0.588
- INTERFERON_GAMMA_RESPONSE-0.583
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.559
- IL6_JAK_STAT3_SIGNALING-0.546
- TNFA_SIGNALING_VIA_NFKB-0.544
- ALLOGRAFT_REJECTION-0.491
- ANGIOGENESIS-0.488
- IL2_STAT5_SIGNALING-0.476
- NOTCH_SIGNALING-0.476
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4PH1MBGR | medulloblastoma | — | 0.981 |
| 2 | BS_ERWT0ZWE | medulloblastoma | — | 0.978 |
| 3 | BS_HD4EJYE3 | medulloblastoma | — | 0.977 |
| 4 | BS_HTEPAKCM | medulloblastoma | — | 0.977 |
| 5 | BS_GNV89A5P | medulloblastoma | — | 0.976 |
| 6 | BS_5PJCHF6V | medulloblastoma | — | 0.975 |
| 7 | BS_J8G4SH4Z | medulloblastoma | — | 0.975 |
| 8 | BS_GE2RVZE6 | medulloblastoma | — | 0.971 |
| 9 | BS_Y8D1F5WW | medulloblastoma | — | 0.970 |
| 10 | BS_QPPPGYP4 | medulloblastoma | — | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.473 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.429 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.315 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.251 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.205 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.036 | Inavolisib | — uncovered |